Skip to main content
TipRanks
Go Ultimate75% OFF

Bausch + Lomb Corporation (S2L) Q3 2026 Earnings Report

1 Followers

DE:S2L Q3 2026 EPS Results

Actual EPS
EUR 0.31
Consensus EPS
EUR 0.19
Beat/Miss
Beat by +EUR 0.11
One Year Ago EPS
EUR 0.16

DE:S2L Q3 2026 Revenue Results

Actual Revenue
EUR 1.25B
Expected Revenue
EUR 1.25B
Beat/Miss
Beat by +EUR 2.67M
YoY Revenue Growth
+7.34%

Earnings Announcement Details

Quarter
Q3 2026
Date
10/28/2026
Time
Before Open
Conference Call
Wednesday, October 28, 2026
DE:S2L Upcoming Earnings

Bausch + Lomb Corporation's next earnings date is estimated for February 24, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:S2L Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Oct 28, 2026|% Change Since:22.29%|
Earnings Call Sentiment|Positive

The call was strongly positive, with broad-based revenue growth, significant adjusted EBITDA and margin expansion, record quarterly cash generation, lower leverage, raised 2026 guidance, and continued momentum across key brands and pipeline programs. The main challenges were foreign-exchange headwinds, lower surgical equipment revenue tied to the placement strategy, slower international contact-lens growth, and the ongoing development and regulatory work required for pipeline programs.

Company Guidance

For 2026, with 1 quarter remaining, the company raised full year revenue guidance by $10 million to a range of $5.450 billion to $5.550 billion, reflecting full year constant currency growth of approximately 6.1% to 8.0%; adjusted EBITDA guidance was raised by $65 million to a range of $1.090 billion to $1.140 billion, implying an adjusted EBITDA margin of approximately 20.3%, about 130 basis points above the full year 2026 outlook provided at Investor Day. The company now estimates a $40 million revenue tailwind from currency, down from approximately $45 million previously; adjusted gross margin is expected to be in the range of 62.5% to 63%, R&D investment in the range of 7.5% to 8.0% of revenue, interest expense approximately $365 million, full year CapEx approximately $285 million, and the adjusted tax rate approximately 18%, slightly below the previous outlook of 19.0%. The company continues to target 3.5x leverage and a 23% EBITDA margin target in 2028.

  • Broad-Based Q3 Revenue GrowthThird-quarter revenue was $1.375 billion, up 8% on a constant-currency basis, with growth across all three segments: Pharmaceuticals increased 11%, Surgical increased 9%, and Vision Care increased 6%.
  • Strong Adjusted EBITDA and Margin ExpansionAdjusted EBITDA increased 34% year over year to $325 million, while adjusted EBITDA margin expanded 460 basis points to 23.6%. The company said the performance reflected disciplined execution, strong commercial performance, favorable product mix, productivity initiatives, and supply-chain and manufacturing execution.
  • Record Q3 Cash Generation and Lower LeverageOperating cash flow was $233 million and free cash flow was $178 million in the third quarter, described as the company's strongest quarterly cash generation since its 2022 IPO. Net leverage declined from 5.7x a year ago to 4.1x at quarter-end, with management stating that its 3.5x target is increasingly achievable.
  • Fourth Consecutive Quarter Delivering Against Investor Day CommitmentsManagement said the third quarter marked the fourth consecutive quarter of delivering against the commitments outlined at Investor Day, with revenue growth and profitability expanding at an even faster rate.
  • Vision Care Growth Across Consumer and Contact LensesVision Care revenue was $774 million, up 6%. Consumer revenue increased 6%, U.S. consumer consumption increased 6%, and contact-lens revenue increased 6%. U.S. contact-lens revenue increased 9% and international contact-lens revenue increased 4%.
  • LUMIFY Continued Strong GrowthLUMIFY generated $66 million of third-quarter revenue, up 38% in the detailed segment results; management also characterized reported revenue growth as 35% in its prepared remarks. The company said the brand has continued to grow more than eight years after launch, with a next-generation LUMIFY product expected to launch in the first half of 2027.
  • Contact Lens Portfolio MomentumDaily SiHy revenue increased 25% and Ultra revenue increased 17%. Management also cited sustained growth across the portfolio, including approximately 17% growth in FRP lenses, and said the portfolio includes spherical, toric, multifocal, and multifocal toric products with additional global rollout opportunity.
  • Strong Pharmaceutical Performance Led by MieboPharmaceutical revenue was $367 million, up 11%. U.S. Pharmaceuticals increased 14%, the dry-eye pharmaceutical portfolio increased 22%, Miebo revenue increased 42% to $119 million, and Xiidra revenue increased 2% to $89 million. Management said Miebo's performance was driven by volume, with average prescriptions of approximately 37,000, while its 2026 gross-to-net structure remained around the mid-seventies.
  • Surgical Growth Led by Premium IOLsSurgical revenue was $234 million, up 9%. Implantables increased 40%, premium IOLs increased 75% in the detailed segment results, and management said reported premium-IOL growth approached 70% in its prepared remarks. Consumables increased 5%, and management said premium IOL adoption is supporting portfolio transition toward higher-margin categories.
  • Gross Margin ImprovementAdjusted gross margin was 64.7%, up 300 basis points year over year. This included a one-time tariff refund of approximately $14 million; excluding that benefit, adjusted gross margin was 63.6%, up from 61.7% in the prior-year quarter. Management attributed the improvement to favorable mix from higher-margin brands and productivity initiatives.
  • Operating Expense Efficiency GainsThe lower fixed-cost structure drove 150 basis points of year-to-date improvement in adjusted SG&A margin. Management said it is continuing to pursue additional efficiency initiatives and is targeting a further 200 basis points of improvement over the next couple of years.
  • Raised 2026 Revenue and EBITDA GuidanceThe company raised full-year 2026 revenue guidance by $10 million to $5.450 billion-$5.550 billion, reflecting a $15 million increase in the underlying business outlook partially offset by $5 million of lower currency tailwinds. Constant-currency growth guidance is approximately 6.1%-8.0%, 30 basis points above the July guidance. Adjusted EBITDA guidance increased by $65 million to $1.090 billion-$1.140 billion.
  • 2026 Margin Outlook Ahead of Investor Day TargetThe midpoint of the updated 2026 guidance implies adjusted EBITDA margin of approximately 20.3%, about 130 basis points above the approximately 19.0% target established at Investor Day and approximately 280 basis points above the 17.5% margin reported for 2025.
  • Improved Full-Year Gross Margin and Tax AssumptionsFull-year adjusted gross margin guidance increased to 62.5%-63.0% from approximately 62%. The adjusted tax-rate outlook was reduced to approximately 18% from 19.0%. Full-year R&D investment is expected to remain 7.5%-8.0% of revenue, while interest expense is expected to be approximately $365 million and CapEx approximately $285 million.
  • Continued R&D and Innovation InvestmentThe company invested $91 million in adjusted R&D in the third quarter and said it will continue advancing its pipeline across dry-eye solutions, surgical technologies, and next-generation contact lenses. Management emphasized that innovation remains fundamental to long-term growth.
  • Progress Across the Product PipelineProject Halo is progressing through internal insertion, tear-dynamics, lens-design, and packaging studies. Project Ilios remains under FDA review with approval still planned by year-end if no further issues are issued by the FDA. The company plans to begin a U.S. myopia study for Halo in Q4, has a mid-December pre-submission meeting planned for its EDOF program, and is planning Phase III studies for its dual dry-eye products.
  • Tonabersat Dry-AMD Program AdvancementFollowing an FDA meeting, the company said its orally administered once-daily tonabersat program for dry AMD, pre-geographic atrophy, or pre-wet AMD is advancing toward a PK and safety study planned for the beginning of next year. Management said the FDA discussion was encouraging regarding the unmet medical need and the product's mechanism of action.
  • Capital Allocation and Balance-Sheet PrioritiesManagement said reducing leverage toward the 3.5x target is a top priority while continuing to invest organically and potentially inorganically. Any acquisitions would be evaluated on an accretive basis and according to the return on investment they can generate.
  • Project Halo Designed for Existing EquipmentManagement said Project Halo is expected to use existing production lines, avoiding the build-out capital intensity associated with new lens manufacturing, and that its starting cost per unit is expected to be attractive.

DE:S2L Earnings History

DE:S2L earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 24, 20272026 (Q4)0.34-0.29――
Oct 28, 20262026 (Q3)0.190.310.1688.89% (+0.15)
Jul 29, 20262026 (Q2)0.140.140.06114.29% (+0.07)
Apr 29, 20262026 (Q1)0.050.07-0.06214.29% (+0.14)
Feb 18, 20262025 (Q4)0.320.290.2328.00% (+0.06)
Oct 29, 20252025 (Q3)0.150.160.155.88% (+0.01)
Jul 30, 20252025 (Q2)0.060.060.12-46.15% (-0.05)
Apr 30, 20252025 (Q1)0.02-0.060.06-200.00% (-0.13)
Feb 19, 20252024 (Q4)0.210.230.224.17% (+0.01)
Oct 30, 20242024 (Q3)0.140.150.2-22.73% (-0.05)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed